SYSTEMIC THERAPY FOR ADVANCED OVARIAN CANCER IN BRCA1 MUTATION CARRIERS -NEW THERAPEUTIC APPROACHES: RESULTS OF A PROSPECTIVE NON-RANDOMIZED MULTI-CENTER STUDY
- Авторлар: Gorodnova T.V1, Sokolenko A.P1, Ivantsov A.O1, Kotiv K.B1, Yakovleva M.G1, Mikheeva O.N2, Mikhaylyuk G.I2, Lisyanskaya A.S3,4, Guseinov K.D1, Nekrasova E.A1, Smirnova O.A1, Sidoruk A.A1, Bondarev N.E1, Matveeva N.S1, Meshkova I.E1, Mikaya N.A1, Petrik S.V1, Manikhas G.M3,4, Protsenko S.A1, Berlev I.V1, Belyaev A.M1, Imyanitov E.N1
-
Мекемелер:
- N.N. Petrov National Medical Research Center of Oncology
- Leningrad Regional Oncological Center
- St. Petersburg State Healthcare Institution “City Clinical Oncology Center"
- Pavlov First St. Petersburg State Medical University
- Шығарылым: № 7 (2018)
- Беттер: 57-63
- Бөлім: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/295471
- ID: 295471
Дәйексөз келтіру
Аннотация
Толық мәтін
Авторлар туралы
T. Gorodnova
N.N. Petrov National Medical Research Center of Oncology
Email: t.gorodnova@mail.ru
PhD, oncologisT., researcher of the Department of oncogynecology St. Petersburg, Russia
A. Sokolenko
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
A. Ivantsov
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
Kh. Kotiv
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
M. Yakovleva
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
O. Mikheeva
Leningrad Regional Oncological CenterSt. Petersburg, Russia
G. Mikhaylyuk
Leningrad Regional Oncological CenterSt. Petersburg, Russia
A. Lisyanskaya
St. Petersburg State Healthcare Institution “City Clinical Oncology Center"; Pavlov First St. Petersburg State Medical UniversitySt. Petersburg, Russia
K. Guseinov
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
E. Nekrasova
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
O. Smirnova
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
A. Sidoruk
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
N. Bondarev
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
N. Matveeva
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
I. Meshkova
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
N. Mikaya
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
S. Petrik
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
G. Manikhas
St. Petersburg State Healthcare Institution “City Clinical Oncology Center"; Pavlov First St. Petersburg State Medical UniversitySt. Petersburg, Russia
S. Protsenko
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
I. Berlev
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
A. Belyaev
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
E. Imyanitov
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
Әдебиет тізімі
- du Bos A., Reuss A., Pujade-Lauraine E., et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009;115(6):1234-Doi: https://doi.org/10.1002/cncr.24149.
- du Bois A., Kristensen G., Ray-Coquard I., et al. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. Oncol. 2016;17(1):78-89. doi: 10.1016/S1470-2045(15)00366-6.
- Берлев И.В., Карачун А.М., Городнова Т.В., и др. Циторедуктивные операции с перитонэктомией у больных раком яичников: технические аспекты и непосредственные результаты. Вопросы онкологии. 2018;65(3.):в печати. [Berlev I.V., Karachun A.M., Gorodnova T.V, et al. Cytoreductive surgery with peritonectomy in patients with ovarian cancer: technical aspects and immediate results. Voprosy onkologii. 2018;65(3.):in press. (In Russ.)].
- Vergote I., Tropé C.G., Amant F, et al.; European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N. Engl. J. Med. 201;363(10):943-53. Doi: 10.1056/ NEJMoa0908806.
- Leary A., Cowan R., Chi D., et al. Primary Surgery or Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: The Debate Continues. Am. Soc. Clin. Oncol. Educ. Book. 2016;35:153-62. Doi: 10.1056/ NEJMoa0908806.
- Lord C.J., Ashworth A. Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat. Med. 2013;19(11):1381-88. doi: 10.1038/nm.3369.
- Sokolenko A.Р., Savonevich E.L., Ivantsov A.O., et al. Rapid selection of BRCA1-proficient tumor cells during neoadjuvant therapy for ovarian cancer in BRCA1 mutation carriers. Cancer Lett. 2017;397:127-32. Doi: https://doi.org/10.1016/j. canlet.2017.03.036
- Kehoe S., Hook J., Nankivell M., et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386(9990):249-57. doi: 10.1016/S0140-6736(14)62223-6.
- Martins F.C., De S., Almendro V., et al. Evolutionary pathways in BRCA1-associated breast tumors. Cancer Discov. 2012;2(6):503-11.
- Suidan R.S., Ramirez P.T., Sarasohn D.M., et al. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecol. Oncol. 2014;134(3):455-61. Doi: https://doi. org/10.1016/j.ygyno.2014.07.002
- Соколенко А.П., Иевлева А.Г., Митюшкина Н.В., и др. Синдром наследственного рака молочной железы и яичников в Российской Федерации. Acta naturae. 2010;4:35-9.
- Bohm S., Faruqi A., Said I., et al. Chemotherapy response score: developmentand validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma. J. Clin. Oncol. 2015;33:2457-63. doi: 10.1200/Jœ.2014.60.5212.
- Maxwell K.N., Wubbenhorst B., Wenz B.M., et al. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers. Nat. Commun. 2017;8(1):319. doi: 10.1038/s41467-017-00388-9.
- Petrillo M., Zannoni G.F., Tortorella L., et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. Am. J. Obstet. Gynecol. 2014;211(6):632.e1-8.
- Bonnefoi H., Litière S., Piccart M., et al.; EORTC 10994/BIG 1-00 Study investigators. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial. Ann. Oncol. 2014;25(6):1128-36. doi: 10.1093/annonc/ mdu118.
- Cortazar Р., Zhang L., Untch M., et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164-72. doi: 10.1016/S0140-6736(13)62422-8.
- Gorodnova T.V., Sokolenko A.Р., Ivantsov A.O., et al. High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation, Cancer Lett. 2015;369:363-67. Doi: 10.1016f.caniet.2015.08.028.
- Byrski T., Gronwald J., Huzarski T., et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J. Clin. Oncol. 2010;28(3):375-79. doi: 10.1200/Jœ.2008. 20.7019.
- Pfeifer W., Sokolenko A.Р., Potapova O.N., et al. Breast cancer sensitivity to neoadjuvant therapy in BRCA1 and CHEK2 mutation carriers and non-carriers. Breast Cancer Res. Treat. 2014;148(3):675-83. doi: 10.1007/s10549-014-3206-1
- Prat J. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Committee on Gynecologic Oncology. Int. J. Gynaecol. Obstet. 2014;124(1):1-5. Doi: 10.1016/j. ijgo.2013.10.001.